Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDemonstrates high affinity for the kainate receptor subtype hGluK1 (formerly hGluR5) (Ki = 0.24 nM) and 600-4000-fold selectivity over both the AMPA receptor subtypes and the homomeric kainate receptor hGluK2 (formerly hGluR6).
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
M. Wt | 325.06 |
Formula | C7H8IN3O4 |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
CAS Number | 140187-25-3 |
PubChem ID | 447196 |
InChI Key | AXXYLTBQIQBTES-BYPYZUCNSA-N |
Smiles | O=C(N1)N(C[C@]([H])(N)C(O)=O)C=C(I)C1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
1.1eq. NaOH | 8.12 | 25 |
The following data is based on the product molecular weight 325.06. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.25 mM | 12.31 mL | 61.53 mL | 123.05 mL |
1.25 mM | 2.46 mL | 12.31 mL | 24.61 mL |
2.5 mM | 1.23 mL | 6.15 mL | 12.31 mL |
12.5 mM | 0.25 mL | 1.23 mL | 2.46 mL |
References are publications that support the biological activity of the product.
Jane et al (1997) Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J.Med.Chem. 40 3645 PMID: 9357531
Patneau et al (1992) Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J.Neurosci. 12 595 PMID: 1371315
Swanson et al (1998) Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol.Pharmacol. 53 942 PMID: 9584222
Wong et al (1994) Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurones. J.Neurosci. 14 3881 PMID: 7515954
Thompson et al (1996) Depolarising effects of certain derivatives of (S) willardiine upon in vitro neonatal rat dorsal roots. Br.J.Pharmacol. 117 331P
If you know of a relevant reference for (S)-(-)-5-Iodowillardiine, please let us know.
Keywords: (S)-(-)-5-Iodowillardiine, (S)-(-)-5-Iodowillardiine supplier, potent, subtype, selective, kainate, agonists, Glutamate, Kainate, Receptors, iGluR, Ionotropic, GluR5, GluK1, 0307, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for (S)-(-)-5-Iodowillardiine include:
Pollok and Reiner (2020) Subunit-selective iGluR antagonists can potentiate heteromeric receptor responses by blocking desensitization. Proc Natl Acad Sci U S A 117 25851 PMID: 32999066
Pansiot et al (2010) Neuroprotective effect of inhaled nitric oxide on excitotoxic-induced brain damage in neonatal rat. Proc Natl Acad Sci U S A 5 e10916 PMID: 20532231
Do you know of a great paper that uses (S)-(-)-5-Iodowillardiine from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review (S)-(-)-5-Iodowillardiine and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.